ZBCN (ZebecNetwork) fluctuated by 40.5% in 24 hours: Institutional capital inflows and product announcements drive resonance
Bitget Pulse2026/03/20 04:29Volatility Overview
In the past 24 hours, the price of ZBCN rebounded from a low of $0.002044 to a high of $0.002872, with the current price quoted at $0.002809, a fluctuation amplitude of 40.5%, showing an overall trend of first declining and then rising. The 24-hour trading volume was approximately $12.53 million, significantly higher than the previous day. On-chain data shows clear signs of net capital inflow, including 85 million ZBCN transferred into Fireblocks institutional custody wallets.
Brief Analysis of Abnormal Movements
- Product Announcement Release: On March 19, Zebec Network announced a new product news, involving key ecosystem partnerships and global payment integration. The project had been preheating earlier, and this event directly triggered the price rebound.
- Institutional/Whale Moves: Within 24 hours, 85 million ZBCN were observed flowing into Fireblocks and Coinbase related wallets, while the daily increase exceeded 14%, indicating signs of institutional accumulation.
- Continued Deflation Expectations: After the final token unlock on March 16, the supply became fixed. Combined with the SuperApp launch and card revenue buyback mechanism, it strengthened the market's confidence in the deflationary narrative.
Market View and Outlook
The mainstream sentiment in the community remains bullish, with X platform discussions focusing on institutional inflows and infrastructure upgrades, predicting a price repricing and the possibility of testing $0.008. Analysts highlight short-term volatility risks, but are optimistic about PayFi's utility-driven long-term prospects. CoinGecko data shows a 24-hour gain of nearly 30%, ranking among the top gainers.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
